MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 - Germany

This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

: mii-exa-onko-molecular-cdk46-protocol

Raw json | Download

{
  "resourceType" : "RequestGroup",
  "id" : "mii-exa-onko-molecular-cdk46-protocol",
  "meta" : {
    "profile" : [
      🔗 "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/StructureDefinition/mii-pr-onko-therapieempfehlung-kombinationstherapie|2027.0.0-ballot.1"
    ]
  },
  "language" : "de",
  "text" : {
    "status" : "generated",
    "div" : "<div xml:lang=\"de\" lang=\"de\"><hr/><p><b>German</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: RequestGroup mii-exa-onko-molecular-cdk46-protocol</b></p><a name=\"de-mii-exa-onko-molecular-cdk46-protocol\"> </a><a name=\"de-hcmii-exa-onko-molecular-cdk46-protocol\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-mii-pr-onko-therapieempfehlung-kombinationstherapie.html\">MII PR Onkologie Therapieempfehlung Kombinationstherapie</a> version: 2027.0.0-ballot.1</p></div><p><b>status</b>: Active</p><p><b>intent</b>: Proposal</p><p><b>code</b>: <span title=\"Codes:{https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ CZ}\">CDK4/6 Inhibitor + Hormontherapie Kombination</span></p><p><b>subject</b>: <a href=\"Patient-mii-exa-onko-molecular-board-patient.html\">Maria Müller  Female, DoB: 1968-07-22 ( https://www.medizininformatik-initiative.de/fhir/sid/patienten#MTB-2024-001)</a></p><p><b>authoredOn</b>: 2024-01-15</p><p><b>reasonReference</b>: <a href=\"Condition-primaertumor-example.html\">Condition Bösartige Neubildung: Brustdrüse, nicht näher bezeichnet</a></p><h3>Actions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Title</b></td><td><b>Description</b></td><td><b>Resource</b></td></tr><tr><td style=\"display: none\">*</td><td>CDK4/6 Inhibitor (pharmazeutische Klasse)</td><td>Beliebiger CDK4/6 Inhibitor: Palbociclib, Ribociclib oder Abemaciclib je nach Verfügbarkeit und Patientenfaktoren</td><td><a href=\"MedicationRequest-mii-exa-onko-cdk46-class-medication.html\">MedicationRequest: status = active; intent = option; medication[x] = Cyclin-abhängige Kinasen (CDK)-Inhibitoren; authoredOn = 2024-01-15; note = Molekulares Tumorboard empfiehlt beliebigen CDK4/6 Inhibitor basierend auf HR+/HER2- Profil. Konkrete Wirkstoffauswahl nach Verfügbarkeit und Patientenfaktoren.</a></td></tr></table></div>"
  },
  "status" : "active",
  "intent" : "proposal",
  "code" : {
    "coding" : [
      {
        "system" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ",
        "code" : "CZ"
      }
    ],
    "text" : "CDK4/6 Inhibitor + Hormontherapie Kombination"
  },
  "subject" : {
    🔗 "reference" : "Patient/mii-exa-onko-molecular-board-patient"
  },
  "authoredOn" : "2024-01-15",
  "reasonReference" : [
    {
      🔗 "reference" : "Condition/primaertumor-example"
    }
  ],
  "action" : [
    {
      "title" : "CDK4/6 Inhibitor (pharmazeutische Klasse)",
      "description" : "Beliebiger CDK4/6 Inhibitor: Palbociclib, Ribociclib oder Abemaciclib je nach Verfügbarkeit und Patientenfaktoren",
      "resource" : {
        🔗 "reference" : "MedicationRequest/mii-exa-onko-cdk46-class-medication"
      }
    }
  ]
}